Abstract
We evaluated the associations between the in vitro activities of ethambutol and rifampin and clinical outcomes of Mycobacterium avium complex (MAC) pulmonary disease (PD). Among 158 patients with MAC-PD, there was no relationship between high MICs for ethambutol and/or rifampin and treatment failure for MAC-PD. Ethambutol and rifampin resistance was common among MAC isolates (rates of 87% and 59%, respectively), but mutations in embB, rpoB, and rpoC were rare, with detection in only 4% of the drug-resistant MAC isolates.
Keywords:
MIC; Mycobacterium avium complex; ethambutol; outcome; rifampin.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use
-
Antitubercular Agents / pharmacology
-
Antitubercular Agents / therapeutic use
-
Drug Therapy, Combination
-
Ethambutol / pharmacology
-
Ethambutol / therapeutic use
-
Humans
-
Lung Diseases* / drug therapy
-
Lung Diseases* / microbiology
-
Mycobacterium avium Complex / genetics
-
Mycobacterium avium-intracellulare Infection* / drug therapy
-
Mycobacterium avium-intracellulare Infection* / microbiology
-
Rifampin / pharmacology
-
Rifampin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Antitubercular Agents
-
Ethambutol
-
Rifampin